PMID- 12542482 OWN - NLM STAT- MEDLINE DCOM- 20030321 LR - 20190705 IS - 0007-1048 (Print) IS - 0007-1048 (Linking) VI - 120 IP - 2 DP - 2003 Jan TI - Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. PG - 251-6 AB - The BCR-ABL-negative chronic myeloproliferative disorders (CMPD) and myelodysplastic/myeloproliferative diseases (MDS/MPD) are a spectrum of related conditions for which the molecular pathogenesis is poorly understood. Translocations that disrupt and constitutively activate the platelet-derived growth factor receptor beta(PDGFRB) gene at chromosome band 5q33 have been described in some patients, the most common being the t(5;12)(q33;p13). An accurate molecular diagnosis of PDGFRB-rearranged patients has become increasingly important since recent data have indicated that they respond very well to imatinib mesylate therapy. In this study, we have tested nine patients with a CMPD or MDS/MPD and a translocation involving 5q31-33 for disruption of PDGFRB by two-colour fluorescence in situ hybridization (FISH) using differentially labelled, closely flanking probes. Normal control interphase cells gave a false positive rate of 3% (signals more than one signal width apart). Six patients showed a pattern of one fused signal (from the normal allele) and one pair of signals separated by more than one signal width in > 85% of interphase cells, indicating that PDGFRB was disrupted. These individuals had a t(1;5)(q21;q33), t(1;5)(q22;q31), t(1;3;5)(p36;p21;q33), t(2;12;5)(q37;q22;q33), t(3;5) (p21;q31) and t(5;14)(q33;q24) respectively. The remaining three patients with a t(1;5)(q21;q31), t(2;5)(p21;q33) and t(5;6)(q33;q24-25) showed a normal pattern of hybridization, with > or = 97% interphase cells with two fusion signals. We conclude that two-colour FISH is useful to determine the presence of a PDGFRB rearrangement, although, as we have shown previously, this technique may not detect subtle complex translocations at this locus. Our data indicate that several PDGFRB partner genes remain to be characterized. FAU - Baxter, E Joanna AU - Baxter EJ AD - Wessex Regional Genetics Laboratory, Salisbury District Hospital, UK. FAU - Kulkarni, Shashikant AU - Kulkarni S FAU - Vizmanos, Jose-Luis AU - Vizmanos JL FAU - Jaju, Rina AU - Jaju R FAU - Martinelli, Giovanni AU - Martinelli G FAU - Testoni, Nicoletta AU - Testoni N FAU - Hughes, George AU - Hughes G FAU - Salamanchuk, Zoryana AU - Salamanchuk Z FAU - Calasanz, Maria Jose AU - Calasanz MJ FAU - Lahortiga, Idoya AU - Lahortiga I FAU - Pocock, Christopher F AU - Pocock CF FAU - Dang, Raymond AU - Dang R FAU - Fidler, Carrie AU - Fidler C FAU - Wainscoat, James S AU - Wainscoat JS FAU - Boultwood, Jacqueline AU - Boultwood J FAU - Cross, Nicholas C P AU - Cross NC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Br J Haematol JT - British journal of haematology JID - 0372544 RN - EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor beta) RN - EC 2.7.10.2 (Fusion Proteins, bcr-abl) SB - IM MH - *Chromosomes, Human, Pair 1 MH - *Chromosomes, Human, Pair 5 MH - Chromosomes, Human, Pair 9 MH - Eosinophilia/genetics MH - Female MH - Fusion Proteins, bcr-abl MH - Humans MH - In Situ Hybridization, Fluorescence MH - Male MH - Myeloproliferative Disorders/*genetics MH - Polymerase Chain Reaction/methods MH - Receptor, Platelet-Derived Growth Factor beta/*genetics MH - Sensitivity and Specificity MH - *Translocation, Genetic EDAT- 2003/01/25 04:00 MHDA- 2003/03/22 04:00 CRDT- 2003/01/25 04:00 PHST- 2003/01/25 04:00 [pubmed] PHST- 2003/03/22 04:00 [medline] PHST- 2003/01/25 04:00 [entrez] AID - 4051 [pii] AID - 10.1046/j.1365-2141.2003.04051.x [doi] PST - ppublish SO - Br J Haematol. 2003 Jan;120(2):251-6. doi: 10.1046/j.1365-2141.2003.04051.x.